A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review

Lorlatinib is a third-generation ALK inhibitor that can overcome the largest number of acquired ALK resistance mutations, including the solvent-front mutation G1202R. Here, we report, for the first time, a novel, sequentially-evolved EML4-ALK variant 3 G1202R/S1206Y double mutation in cis detected in a patient with ALK-positive NSCLC after disease progression on sequential crizotinib, alectinib, and then lorlatinib. Three-dimensional computer modeling of this double mutation and other G1202R-based double mutations with lorlatinib (ALK G1202R/L1196M, ALK G1202R/F1174C, ALK G1202R/l1198F, ALK G1202R/G1269A) were provided to reveal how these double mutations may confer resistance to lorlatinib through diverse steric hindrances in the ALK kinase domain. In addition, we performed a comprehensive literature review on published acquired double or triple ALK mutations that are resistant to lorlatinib from both patient samples and in vitro mutagenesis experiments. READ ARTICLE

Journal of Thoracic Oncology DOI: 10.1016/j.jtocrr.2020.100116

Authors: Viola W. Zhu, Misako Nagasaka, Russell Madison, Alexa B. Schrock, Jean Cui, Sai-Hong Ignatius Ou

Review PaperKirk SmithNovember 1, 2020TKI Resistance, Resistance mutation

Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI–Treated Non–Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy

Mutation profiling using liquid biopsy has become a promising approach for monitoring tumor genomic evolution when tissue biopsy is not available. READ ARTICLE

Clinical Lung Cancer DOI:10.1016/j.cllc.2019.02.014

Authors: MeijuanDing, Lili Deng, Ruoying Yu, Dan Lu, Yun Bai, Xue Wu, Yang W. Shao, Yu Yang

Case StudyKirk SmithFebruary 27, 2019ALK secondary mutation, EML4-ALK, Longitudinal monitoring, Resistance mutation, Target sequencing